NEW YORK--(BUSINESS WIRE)--BioLegend, Inc. (“BioLegend”) and the New York Genome Center (“NYGC”) announced today that they have entered into an exclusive worldwide license and collaborative research ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE - In this Feb. 11, 2021, file photo is the exterior of the PerkinElmer lab in Valencia, Calif. PerkinElmer will spend about ...

PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...

SAN DIEGO, CA--(Marketwire - Mar 7, 2013) - BioLegend in San Diego, CA, a leading provider of antibodies and reagents for biomedical research, has been granted ISO 9001:2008 certification for ...

View post: Oppenheimer has a warning for investors before the fall Scientific instrument maker PerkinElmer (PKI) said Monday it has agreed to buy BioLegend, a provider of antibodies and reagents, for ...

San Diego-based Biotech firm BioLegend Inc. has begun work on a new campus in Miramar, with an expected project cost of more than $100 million. A company spokeswoman said a ground-breaking was held ...

Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash-and-stock ...

PerkinElmer Inc. said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. PerkinElmer said Monday the transaction is ...

PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...

July 26 (Reuters) - Medical diagnostic firm PerkinElmer Inc (PKI.N), opens new tab said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, ...